AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

PYC THERAPEUTICS LTD

2.300

-0.020-0.86%

Volume:3.18M

Turnover:7.31M

Market Cap:2.26B

PE:-38.92

High:2.340

Open:2.320

Low:2.260

Close:2.320

52wk High:2.620

52wk Low:0.847

Shares:983.26M

Float Shares:348.08M

Volume Ratio:0.96

T/O Rate:0.91%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.059

EPS(LYR):-0.059

ROE:-10.14%

ROA:-8.05%

PB:3.26

PE(LYR):-38.92

Loading ...

Overview Company News Filings

Concept

no data

No relevant data is available

Capital Flow

Inflow:

Outflow:

News

PYC Therapeutics Says First Patient Dosed in Open-Label Extension of Drug Candidate Study in Polycystic Kidney Disease

MT Newswires Live

ASX Biggest Gainers

MT Newswires Live

Why PYC Therapeutics (ASX:PYC) Is Up 10.5% After Narrowing Its Full-Year Net Loss

Simply Wall St.

PYC Therapeutics (ASX:PYC) Shares Chase Revenue Growth Despite Deep Losses

Simply Wall St.

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.imtigers.com/stock/PYC.AU"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"PYC.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"PYC.AU\",,,,,undefined,":{"symbol":"PYC.AU","market":"AU","secType":"STK","nameCN":"PYC THERAPEUTICS LTD","latestPrice":2.3,"timestamp":1789107120000,"preClose":2.32,"halted":0,"volume":3180085,"delay":0,"changeRate":-0.008620689655172422,"nameEN":"PYC THERAPEUTICS LTD","floatShares":348081085,"shares":983260447,"eps":-0.0591,"marketStatus":"Market Closed","change":-0.02,"latestTime":"09-11 16:12:00 AEST","open":2.32,"high":2.34,"low":2.26,"amount":7308704,"amplitude":0.034483,"askPrice":2.3,"askSize":36654,"bidPrice":2.25,"bidSize":3000,"shortable":3,"etf":0,"ttmEps":-0.0591,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1789344000000},"marketStatusCode":7,"adr":0,"exchange":"ASX","adjPreClose":2.32,"openAndCloseTimeList":[[1789084800000,1789106400000]],"volumeRatio":0.9607068123832644,"lotSize":1,"tradeCurrency":"AUD","auctionPricing":{"symbol":"PYC.AU","preClose":2.32,"auctionPrice":2.29,"auctionVolume":160850,"auction":3,"marketStatus":"盘后竞价","timestamp":1789107003558}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"PYC.AU\",,,,,undefined,":{"symbol":"PYC.AU","floatShares":348081085,"roa":"-8.05%","roe":"-10.14%","lyrEps":-0.0591,"volumeRatio":0.9607068123832644,"shares":983260447,"dividePrice":0,"high":2.34,"amplitude":0.034483,"preClose":2.32,"low":2.26,"week52Low":0.847,"pbRate":"3.26","psRate":"87.00","week52High":2.62,"institutionHeld":0,"latestPrice":2.3,"committee":-0.848691,"eps":-0.0591,"divideRate":0,"volume":3180085,"delay":0,"ttmEps":-0.0591,"open":2.32,"prevYearClose":1.655,"prevWeekClose":2.49,"prevMonthClose":2.32,"prevQuarterClose":1.685,"fiveDayClose":2.49,"twentyDayClose":2.14,"sixtyDayClose":1.52,"dividendGrowthYears":0,"fiveYearAvgDividendRate":0},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/PYC.AU\",params:#limit:5,,,undefined,":[{"market":"AU","date":"2024-11-15","symbol":"PYC.AU","defaultRemindTime":1731625200000,"type":"split","dateTimestamp":1731589200000,"forFactor":10,"toFactor":1,"ratio":10},{"market":"AU","date":"2024-03-18","symbol":"PYC.AU","defaultRemindTime":1710716400000,"type":"split","dateTimestamp":1710680400000,"forFactor":988235,"toFactor":1000000,"ratio":0.988235}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"PYC.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"PYC.AU\",pageSize:4,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2666511339","title":"PYC Therapeutics Says First Patient Dosed in Open-Label Extension of Drug Candidate Study in Polycystic Kidney Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2666511339","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666511339?lang=en_us&edition=fundamental","pubTime":"2026-09-11 07:28","pubTimestamp":1789082915,"startTime":"0","endTime":"0","summary":"PYC Therapeutics  said the first patient was dosed in the Part D open-label extension of the ongoing multiple-ascending dose study of its PYC-003 drug candidate in polycystic kidney disease patients, according to a Friday Australian bourse filing.This patient has been receiving the drug candidate for a period of four months and will continue to receive PYC-003 every six weeks for up to 24 months.The objective of the ongoing study is to determine the safety and tolerability profile and optimal dosing regimen of the drug candidate in a repeat-dose setting before a proposed transition to a registrational trial.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LENZ","BK4007","BK4539","PYC.AU","BK4139","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664033823","title":"ASX Biggest Gainers","url":"https://stock-news.laohu8.com/highlight/detail?id=2664033823","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664033823?lang=en_us&edition=fundamental","pubTime":"2026-09-03 11:14","pubTimestamp":1788405296,"startTime":"0","endTime":"0","summary":"Here are the ASX-listed companies with the biggest gains on Thursday.Southgold 2 : +8%, AU$12.27Phylogica : +7%, AU$2.61OrezOne : +6%, AU$2.75Block : +5%, AU$113.81Telix Pharmaceuticals : +5%, AU$16.44Kingsgate Consolidated : +4%, AU$5.39Deep Yellow : +4%, AU$1.61Resolute Mining : +4%, AU$1.44Perseus Mining : +4%, AU$6.66Life360 : +4%, AU$19.92","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ORE.AU","PRU.AU","TLX","BK7104","SX2.AU","BK4139","DYL.AU","XYZ.AU","BK7506","BK7067","BK7016","BK7083","TLX.AU","360.AU","KCN.AU","RSG.AU","PYC.AU","BK7158"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664881204","title":"Why PYC Therapeutics (ASX:PYC) Is Up 10.5% After Narrowing Its Full-Year Net Loss","url":"https://stock-news.laohu8.com/highlight/detail?id=2664881204","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664881204?lang=en_us&edition=fundamental","pubTime":"2026-09-01 05:15","pubTimestamp":1788210928,"startTime":"0","endTime":"0","summary":"PYC Therapeutics Limited recently reported full-year results for the period ended June 30, 2026, with revenue rising to A$39.68 million from A$26.17 million and its net loss narrowing to A$43.34 million compared with A$50.3 million a year earlier.\nThe improvement in both top-line revenue and loss per share suggests the business is scaling its operations while gradually reducing the financial burden on shareholders.\nWe will now examine how this combination of higher revenue and a smaller...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-pyc/pyc-therapeutics-shares/news/why-pyc-therapeutics-asxpyc-is-up-105-after-narrowing-its-fu","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-pyc/pyc-therapeutics-shares/news/why-pyc-therapeutics-asxpyc-is-up-105-after-narrowing-its-fu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7067","PYC.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663010707","title":"PYC Therapeutics (ASX:PYC) Shares Chase Revenue Growth Despite Deep Losses","url":"https://stock-news.laohu8.com/highlight/detail?id=2663010707","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663010707?lang=en_us&edition=fundamental","pubTime":"2026-08-30 04:19","pubTimestamp":1788034748,"startTime":"0","endTime":"0","summary":"PYC Therapeutics stock closed at A$2.25 on Friday after a strong run over the past month, yet the fresh numbers still tell a story of a biotech deep in investment mode rather than profit harvest. The headline is the loss from continuing operations of A$43.8 million over the trailing twelve months, set against revenue of A$39.7 million. For long term holders, the bigger question now is how to weigh that loss profile against a P/B of 3.2x, which sits below both direct peers and the broader...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-pyc/pyc-therapeutics-shares/news/pyc-therapeutics-asxpyc-shares-chase-revenue-growth-despite","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-pyc/pyc-therapeutics-shares/news/pyc-therapeutics-asxpyc-shares-chase-revenue-growth-despite","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["PYC.AU"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":4,"totalPage":7,"pageCount":1,"totalSize":27,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/PYC.AU\",params:#limit:6,delay:true,,,undefined,":[]}}